No Data
No Data
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains $60 price target.
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin
Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments
No Data